QC
APLS

Quent Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Quent Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-217
Closed -$8.73K – 1654
2026
Q1 		$8.73K Buy
217
+69
+47% +$1.49K ﹤0.01% 1184
2025
Q4 		$3.72K Sell
148
-297
-67% -$6.97K ﹤0.01% 1313
2025
Q3 		$10.1K Buy
+445
New +$10.4K ﹤0.01% 1008
2025
Q2 		– Sell
-49
Closed -$1.07K – 339
2025
Q1 		$1.07K Hold
49
– – ﹤0.01% 1204
2024
Q4 		$1.56K Sell
49
-94
-66% -$2.83K ﹤0.01% 1200
2024
Q3 		$4.12K Hold
143
– – ﹤0.01% 1139
2024
Q2 		$5.49K Buy
143
+119
+496% +$5.39K ﹤0.01% 1069
2024
Q1 		$1.41K Buy
24
+17
+243% +$1.08K ﹤0.01% 1267
2023
Q4 		$419 Buy
7
+2
+40% +$101 ﹤0.01% 1296
2023
Q3 		$190 Buy
+5
New +$220 ﹤0.01% 1296

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Quent Capital's APLS Position: Q2 2026 in Review

Quent Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 217 shares — an estimated $8.73K sold.

Quent Capital first reported a position in APLS in Q3 2023 and held it in 10 quarters. The position peaked at $10.1K in Q3 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Quent Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quent Capital sold 217 Apellis Pharmaceuticals shares in Q2 2026, an estimated $8.73K.
  • Quent Capital first reported a position in Apellis Pharmaceuticals in Q3 2023 and held it in 10 quarters.
  • Quent Capital's Apellis Pharmaceuticals position peaked at $10.1K in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Quent Capital's 13F filing for Q2 2026, filed 7 Aug 2026.